MEDTRONIC PLC

Medtronic’s planned spin‑off of its MiniMed unit seeks to unlock shareholder value, sharpen focus on core medical devices, and adapt to the high‑margin digital health market.

Medtronic’s structured exchange offer lets shareholders swap for MiniMed shares, aiming to unlock diabetes‑care value while ensuring regulatory compliance and operational continuity.

Discover Medtronic PLC’s Q1 2027 earnings outlook: revenue growth, cost‑cuts, AI health tech, and Medicare rebate impact—key insights for savvy investors.

MEDTRONIC PLC Q1 2024: €1.52 bn revenue, 5.8 % growth, driven by cardiac rhythm and neurostimulation sales, with steady guidance amid easing supply‑chain pressures.

Medtronic’s Q1 earnings hit guidance, boosting revenue from cardiovascular & diabetes products while raising R&D spend and launching a new PCI system.

Medtronic’s insider trades and litigation verdicts reveal leadership confidence in a $1.2 B product pipeline, while a $62 M hernia‑mesh judgment underscores rising legal risks and regulatory scrutiny.

Medtronic’s stock edges up 2% amid healthcare‑sector optimism, highlighting resilient growth in cardiac and neurovascular therapies despite regulatory and supply‑chain headwinds.

Medtronic shares dip after June rally – explore how revenue growth, margin pressures, AI surgery tools and digital health gains shape next‑quarter earnings and valuation prospects.

Medtronic PLC’s shares surge as investors shift toward defensive healthcare stocks, highlighting the company’s solid growth and the market’s pivot away from tech overvaluation.

Medtronic’s Q4 2025/26 earnings beat estimates with a 2.8% revenue lift, strong EPS growth, and a 0.5% dividend hike—insights into its cardiovascular, diabetes, and drug‑delivery outlook.